<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-31-03-2026-shutterstock_1700459161-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-31-03-2026-shutterstock_1700459161-430x241.jpg"/>
                                    
                                    <figcaption>CIB-301 targets solid tumours using a fully human CAR scFv. Credit: Vshivkova / Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                        
<figure class="wp-block-image size-large"></figure>



<p>uBriGene Biosciences has signed a strategic partnership with Cellinfinity BIO to advance the clinical development of in vivo chimeric antigen receptor T-cell (CAR-T) therapy programmes for haematologic and solid tumours.</p>



<p>The partnership focuses on progressing Cellinfinity BIO’s programmes CIB-301 and CIB-350.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Idecabtagene Vicleucel in Multiple Myeloma (Ka... </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>NPVM: Alaunos Therapeutics Inc's Gene Therapy 2 for Oncology </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>uBriGene’s LVV Turbo platform will provide good manufacturing practice (GMP) lentiviral vector manufacturing, production, process development, and regulatory support for these therapies.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>The platform integrates three technologies: a fully closed downstream purification process, the ultra-T enhancer, and a high-productivity 293TH suspension cell line.</p>



<p>It achieves up to 80% recovery during purification and boosts T-cell transduction titres by five times.</p>



<p>CIB-301 targets solid tumours with a fully human CAR single-chain variable fragment (scFv) designed for low off-target risk.</p>



<p>It addresses tumour antigens related to colorectal cancer, endometrial cancer, non-small cell lung cancer, ovarian cancer, and renal cell carcinoma.</p>



<p>CIB-350 targets autoimmune diseases and haematologic malignancies with a bispecific CAR design able to target two B-cell antigens simultaneously.</p><div id="slot-two"></div>



<p>uBriGene offers integrated contract development and manufacturing organisation (CDMO) and contract research organisation (CRO) services for cell therapies, viral vectors, and ribonucleic acid (RNA)-related products.</p>



<p>Its global GMP Centers of Excellence support clients in developing next-generation therapies.</p>



<p>Cellinfinity BIO’s platforms focus on precise T-cell modulation for solid tumours, aiming to enhance persistence and safety while demonstrating anti-tumour activity in preclinical models.</p>



<p>uBriGene co-founder and CTO Dr Sun Xiulian said: “We are excited about this strategic partnership with Cellinfinity Bio. In vivo CAR-T technologies have the potential to significantly reduce treatment costs.</p>



<p>“Leveraging our highly productive LVV Turbo lentiviral vector platform and GMP manufacturing expertise, we aim to lower the cost of goods for CAR-T therapies, improving patient accessibility and affordability.”</p>



<p><em>Cell &amp; Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva</em>.</p>



<p><em>Editorial content is independently produced and follows the </em>highest standards <em>of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.</em></p>
<div id="slot-three"></div><p></p>



<div>
    
</div>

159892

<p>uBriGene Biosciences has partnered with Cellinfinity BIO to advance in vivo CAR-T therapy for haematologic and solid tumours. The collaboration focuses on CIB-301 and CIB-350 programmes, utilizing uBriGene’s LVV Turbo platform for GMP lentiviral vector manufacturing. CIB-301 targets solid tumours with a fully human CAR scFv, while CIB-350 addresses autoimmune diseases and haematologic malignancies. The partnership aims to reduce treatment costs and improve patient accessibility to CAR-T therapies.</p>

Pharmaceutical Technology

Proshares Ultra Nasdaq Biotech

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

iShares Biotechnology ETF

Ping An CSI Medicine and Medical Device Innovation ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Invesco Biotechnology & Genome ETF

E Fund CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Tianhong CNI BIOMEDICINE ETF

SPDR S&P Health Equip

iShares US Pharma

ICBCCS SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Unity Biotechnology

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

Guotai CSI Bio-medicine ETF

ALPS Medical Breakthrough

Boundless Bio

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

Beigene

Invesco Nasdaq Biotechnology ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

BeOne Medicines

Penghua SSE STAR Biology and Medicine ETF

SPDR S&P Biotech

VG Health

VanEck Biotech ETF

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Mustang Bio

Bioxcel Therap

ChinaAMC SSE STAR Biology and Medicine ETF

uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies